Physician profile
James Patrick Herrington
NPI 1386710457
$3,304.98
in general payments reported to CMS, 2019-2025
32 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $494 · 2021: $374 · 2022: $324 · 2023: $651 · 2024: $564 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $394.87 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $340.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $223.16 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.22 | 2019-2023 | Trulance, Xifaxan |
| Pfizer INC. | $184.33 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $167.50 | 2019-2022 | |
| Celgene Corporation | $165.94 | 2021-2024 | Zeposia |
| Medtronic, INC. | $116.85 | 2021 | |
| Daiichi Sankyo INC. | $77.90 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $67.11 | 2023-2024 | Ibsrela |
| Romark Laboratories, Lc | $54.15 | 2019-2020 | |
| Qol Medical, LLC | $52.64 | 2020-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $31.26 | 2021-2023 | |
| Madrigal Pharmaceuticals | $29.65 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.87 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $27.14 | 2025 | Libtayo |
| Ironwood Pharmaceuticals, INC | $26.52 | 2021-2023 | Linzess |
| Merck Sharp & Dohme LLC | $20.62 | 2024 | Dificid |
| Fresenius Kabi USA, LLC | $19.77 | 2023 | Idacio |
| Ipsen Biopharmaceuticals, INC | $18.19 | 2025 | Iqirvo |
| Celltrion USA INC. | $18.14 | 2024 | Vegzelma |
| Novo Nordisk INC | $17.84 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $17.56 | 2025 | |
| Genentech USA, INC. | $17.54 | 2025 | Polivy |
| Amgen INC. | $15.46 | 2023 | Avsola, Amjevita |
| Concordia Pharmaceuticals INC. | $14.91 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.87 | 2025 | Givlaari |
| Ucb, INC. | $14.87 | 2019 | |
| Biocon Biologics INC | $14.26 | 2025 | Yesintek |
| Cook Medical LLC | $13.80 | 2022 | |
| Valinor Pharma, LLC | $13.10 | 2023 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Herrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.